title: Effect of cyclophosphamide in active nonviral cirrhosis.
abstract: The immunologic effects of cyclophosphamide were studied in 16 patients with active nonviral liver cirrhosis with a view to improving the pathogenetic treatment of these diseases. After months of cyclophosphamide administration first in doses of 100 mg/day (for 14 days) then in doses of 200 mg per week, the hypergammaglobulinemia present at entry was reduced significantly from 2.55 +/- 0.35 g/dl to 1.71 +/- 0.17 g/dl concomitantly with the proportional increase of the active suppressor T lymphocytes, from 29.3 +/- 3.59% to 38.0 +/- 2.1%. The use of smaller doses of cyclophosphamide, i.e., 200 mg/week, allowed the maintenance of its immunosuppressive properties and prevented its side effects.
authors.affiliation: 3rd Medical Clinic, Institute of Medicine and Pharmacy, Cluj-Napoca, Romania.
authors.forename: P
authors.initials: P
authors.lastname: Szanto
authors.forename: L
authors.initials: L
authors.lastname: Stanciu
authors.forename: E
authors.initials: E
authors.lastname: Togănel
authors.forename: D
authors.initials: D
authors.lastname: Dejica
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006942:Hypergammaglobulinemia / Q000188:drug therapy / Q000276:immunology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000276:immunology; D008104:Liver Cirrhosis, Alcoholic / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D003520:Cyclophosphamide